CMS Approves SINUVA® Sinus Implant for Reimbursement with New C-Code and Pass-Through Payment Status
SINUVA is a non-surgical, corticosteroid-eluting implant for the treatment of nasal polyps in adult patients who have had ethmoid sinus surgery.
Intersect ENT Announces Launch of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
4/2/18: The new treatment is clinically proven to reduce polyps and symptoms of nasal congestion.
Intersect ENT Announces FDA Approval of SINUVA™ Sinus Implant, a New In-Office Treatment Option for Recurrent Nasal Polyps
12/11/17: Intersect ENT, Inc. today announced that it has received approval from the U.S. Food and Drug Administration for the SINUVA™ (mometasone furoate) Sinus Implant, a new targeted approach to treating recurrent nasal polyp disease in patients who have had previous ethmoid sinus surgery.
Presentation of a Meta-Analysis From Two Randomized Studies Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant Announced by Intersect ENT
Intersect ENT, Inc. (NASDAQ: XENT), announced presentation of a meta-analysis from two randomized studies evaluating the safety and efficacy of SINUVA™, an investigational steroid releasing sinus implant. The two studies evaluated the sinus implant in patients with recurrent...
Lisa Earnhardt, president and CEO of Intersect ENT, “The SINUVA implant offers the potential to provide a less invasive and more cost-effective solution, performed easily in the doctor’s office, for patients suffering from persistent chronic sinusitis. She went...